TESARO, Inc. (NASDAQ:TSRO) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

A number of other equities analysts also recently issued reports on the company. Credit Suisse Group set a $198.00 price target on TESARO and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Leerink Swann dropped their price target on TESARO from $164.00 to $143.00 and set a “market perform” rating on the stock in a research report on Tuesday, June 20th. Gabelli initiated coverage on TESARO in a research report on Friday, July 7th. They set a “buy” rating and a $175.00 price target on the stock. Cann reaffirmed a “buy” rating and set a $199.00 price objective on shares of TESARO in a research report on Friday, September 8th. Finally, BidaskClub downgraded TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO presently has a consensus rating of “Buy” and a consensus target price of $170.74.

TESARO (NASDAQ TSRO) opened at 119.11 on Tuesday. The stock’s market cap is $6.45 billion. The firm’s 50-day moving average price is $122.36 and its 200 day moving average price is $134.80. TESARO has a 12 month low of $96.52 and a 12 month high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. During the same period in the previous year, the company posted ($1.28) EPS. TESARO’s quarterly revenue was down 17.6% compared to the same quarter last year. On average, analysts anticipate that TESARO will post ($8.63) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/10/valuengine-downgrades-tesaro-inc-tsro-to-sell.html.

In other TESARO news, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at $1,171,300. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the completion of the sale, the senior vice president now directly owns 6,943 shares in the company, valued at $823,439.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,692 shares of company stock worth $4,628,976. 34.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Tobam acquired a new stake in TESARO in the second quarter valued at approximately $20,189,000. Sphera Funds Management LTD. acquired a new stake in TESARO in the second quarter valued at approximately $7,692,000. Trellus Management Company LLC grew its holdings in TESARO by 12.3% in the second quarter. Trellus Management Company LLC now owns 8,419 shares of the biopharmaceutical company’s stock valued at $1,177,000 after purchasing an additional 919 shares during the period. Fiera Capital Corp acquired a new stake in TESARO in the second quarter valued at approximately $18,451,000. Finally, Swiss National Bank grew its holdings in TESARO by 122.5% in the second quarter. Swiss National Bank now owns 137,000 shares of the biopharmaceutical company’s stock valued at $19,161,000 after purchasing an additional 75,422 shares during the period.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.